We are an innovative biopharmaceutical company developing and commercializing a pipeline of drug candidates in the critical care space. Our pipeline consists of two late-stage, first-in-class drug product candidates and one preclinical program addressing multiple indications with large unmet medical needs.
Our lead clinical candidate Sovateltide is a highly selective Endothelin-B receptor agonist in phase III development for the treatment of acute cerebral ischemic stroke.
Our second clinical phase III candidate centhaquine is a novel, first-in-class resuscitative agent free of arterial constriction for the treatment of hypovolemic shock.
Our lead clinical candidate Sovateltide is a highly selective Endothelin-B receptor agonist in phase III development for the treatment of acute cerebral ischemic stroke.
Our second clinical phase III candidate centhaquine is a novel, first-in-class resuscitative agent free of arterial constriction for the treatment of hypovolemic shock.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Illinois
Company HQ Country:
United States
Year Founded:
2010
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
Sovateltide
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
